CL2008000539A1 - Producto farmaceutico que comprende un compuesto derivado de heterocilo espiro condensado, un agonista del receptor de glucocorticoides y opcionalmente un agonista beta2; y su uso para el tratamiento de enfermedades de las vias aereas, tales como epo - Google Patents
Producto farmaceutico que comprende un compuesto derivado de heterocilo espiro condensado, un agonista del receptor de glucocorticoides y opcionalmente un agonista beta2; y su uso para el tratamiento de enfermedades de las vias aereas, tales como epoInfo
- Publication number
- CL2008000539A1 CL2008000539A1 CL200800539A CL2008000539A CL2008000539A1 CL 2008000539 A1 CL2008000539 A1 CL 2008000539A1 CL 200800539 A CL200800539 A CL 200800539A CL 2008000539 A CL2008000539 A CL 2008000539A CL 2008000539 A1 CL2008000539 A1 CL 2008000539A1
- Authority
- CL
- Chile
- Prior art keywords
- agonist
- heteroycle
- espiro
- glucocorticoid
- epo
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 229940124748 beta 2 agonist Drugs 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- 239000003862 glucocorticoid Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 229940127557 pharmaceutical product Drugs 0.000 title 1
- 208000023504 respiratory system disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89124407P | 2007-02-23 | 2007-02-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2008000539A1 true CL2008000539A1 (es) | 2008-10-10 |
Family
ID=39710315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200800539A CL2008000539A1 (es) | 2007-02-23 | 2008-02-22 | Producto farmaceutico que comprende un compuesto derivado de heterocilo espiro condensado, un agonista del receptor de glucocorticoides y opcionalmente un agonista beta2; y su uso para el tratamiento de enfermedades de las vias aereas, tales como epo |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110124613A1 (es) |
| EP (1) | EP2120935A4 (es) |
| AR (1) | AR065453A1 (es) |
| CL (1) | CL2008000539A1 (es) |
| PE (1) | PE20090491A1 (es) |
| TW (1) | TW200848035A (es) |
| UY (1) | UY30935A1 (es) |
| WO (1) | WO2008103126A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009543860A (ja) * | 2006-07-19 | 2009-12-10 | アストラゼネカ・アクチエボラーグ | 新規三環系スピロピペリジン化合物、それらの合成およびケモカイン受容体活性モジュレーターとしてのそれらの使用 |
| UY32521A (es) * | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Combinación para emplear en el tratamiento de enfermedades respiratorias |
| WO2012163848A1 (en) | 2011-05-27 | 2012-12-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of crohn's disease |
| WO2013060865A1 (en) | 2011-10-28 | 2013-05-02 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| WO2016100823A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute, Inc. | Dopamine d2 receptor ligands |
| WO2016100940A1 (en) * | 2014-12-19 | 2016-06-23 | The Broad Institute, Inc. | Dopamine d2 receptor ligands |
| GB201918692D0 (en) | 2019-12-18 | 2020-01-29 | Cambridge Entpr Ltd | Treatment and prognosis of pancreatic cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2373186A (en) * | 2001-02-23 | 2002-09-18 | Astrazeneca Ab | Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation |
| GB0207436D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| SE0202133D0 (sv) * | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Novel compounds |
| SE0303090D0 (sv) * | 2003-11-20 | 2003-11-20 | Astrazeneca Ab | Novel compounds |
| SE0303280D0 (sv) * | 2003-12-05 | 2003-12-05 | Astrazeneca Ab | Novel compounds |
| SE0303541D0 (sv) * | 2003-12-22 | 2003-12-22 | Astrazeneca Ab | New compounds |
| JP2009506029A (ja) * | 2005-08-26 | 2009-02-12 | アストラゼネカ・アクチエボラーグ | 呼吸器疾患、特に慢性閉塞性肺疾患(copd)および喘息の処置に使用し得る化合物の組み合わせ |
| TW200744612A (en) * | 2005-08-26 | 2007-12-16 | Astrazeneca Ab | New combination |
| JP2009543860A (ja) * | 2006-07-19 | 2009-12-10 | アストラゼネカ・アクチエボラーグ | 新規三環系スピロピペリジン化合物、それらの合成およびケモカイン受容体活性モジュレーターとしてのそれらの使用 |
-
2008
- 2008-02-21 EP EP08712832A patent/EP2120935A4/en not_active Withdrawn
- 2008-02-21 US US12/527,754 patent/US20110124613A1/en not_active Abandoned
- 2008-02-21 WO PCT/SE2008/050204 patent/WO2008103126A1/en not_active Ceased
- 2008-02-22 CL CL200800539A patent/CL2008000539A1/es unknown
- 2008-02-22 PE PE2008000373A patent/PE20090491A1/es not_active Application Discontinuation
- 2008-02-22 AR ARP080100757A patent/AR065453A1/es unknown
- 2008-02-22 TW TW097106287A patent/TW200848035A/zh unknown
- 2008-02-22 UY UY30935A patent/UY30935A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20090491A1 (es) | 2009-05-31 |
| EP2120935A1 (en) | 2009-11-25 |
| EP2120935A4 (en) | 2011-06-22 |
| AR065453A1 (es) | 2009-06-10 |
| US20110124613A1 (en) | 2011-05-26 |
| UY30935A1 (es) | 2008-09-30 |
| WO2008103126A1 (en) | 2008-08-28 |
| TW200848035A (en) | 2008-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2007003755A1 (es) | Compuestos derivados de indol; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de afecciones o trastornos mediados por receptores s1p1 tales como enfermedades autoinmunitarias, asma, neuropatias, artritis, diabe | |
| WO2010141768A3 (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
| WO2012037410A3 (en) | Estrogen receptor modulators and uses thereof | |
| WO2011156518A3 (en) | Estrogen receptor modulators and uses thereof | |
| PH12014501351A1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
| TWI562994B (en) | Fgf receptor (fgfr) agonist dimeric compounds, process for the preparation thereof and therapeutic use thereof | |
| WO2011041462A3 (en) | Polycyclic compounds as lysophosphatidic acid receptor antagonists | |
| IL233325A0 (en) | Dimeric compounds as an agonist for the fgfr (fgf) receptor, a process for their preparation and their therapeutic use | |
| CL2008000539A1 (es) | Producto farmaceutico que comprende un compuesto derivado de heterocilo espiro condensado, un agonista del receptor de glucocorticoides y opcionalmente un agonista beta2; y su uso para el tratamiento de enfermedades de las vias aereas, tales como epo | |
| CL2007001887A1 (es) | Compuestos derivados de bifensustuidas por tetrazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades asociadas con los receptores purinergicos de p2x, tales como trastornos gastrointes | |
| CL2007002121A1 (es) | Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab | |
| CL2007002099A1 (es) | Compuestos derivados de 3h-espiro(1-benzofuran-2,4'-piperidina); proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento de enfermedades respiratorias, tales como epoc y asma. | |
| UA98839C2 (en) | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors | |
| WO2010039977A3 (en) | Heteroaryl antagonists of prostaglandin d2 receptors | |
| CL2008000641A1 (es) | Compuestos derivados de amidas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del insomnio, disfuncion sexual, esquizofrenia, entre otras enferme | |
| WO2014066799A3 (en) | Modulators of resistant androgen receptor | |
| WO2010085820A3 (en) | Tricyclic compounds as antagonists of prostaglandin d2 receptors | |
| ZA201008886B (en) | Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders | |
| CL2007002643A1 (es) | Compuestos derivados de 5-fenil-nicotinamida, moduladores del receptor de cb1; procedimiento de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de trastornos de la nutricion, diabetes tipo ii y dependencia de sustan | |
| CL2008000289A1 (es) | Compuestos derivados de pirano[2,3-b]piridina, moduladores del receptor cannabinoide-1; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como psicosis, enfermedad de alzheimer, migrana, enfermedad de parkinson, asma y obesida | |
| CL2011000184A1 (es) | Compuestos derivados de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno; agonista de receptores de melatonina; proceso para la preparacion de los compuestos; composicion farmaceutica que comprende a los compuestos; y su uso de los compuestos en la preparacion de medicamentos. | |
| UY33529A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias? | |
| CL2007003503A1 (es) | Compuestos derivados de indol-2-il-carbonil-piperidina-benzoimidazolona y de indol-2-il-carbonil-piperidina-benzoxazolona, antagonistas del receptor de la v1a; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de dismenorrea | |
| CL2008000540A1 (es) | Producto farmaceutico que comprende un compuesto derivado de heterociclo sustituido o herterociclo espiro condensado y un antagonista muscarinico; y su uso para el tratamiento de enfermedades de las vias aereas tales como epoc o asma. | |
| CR20110045A (es) | Derivados de estratrienos que comprenden bioisosteros heterociclicos para el anillo fenëlico a |